Ривароксабан у пациентов с острым коронарным синдромом - еще один камень в фундамент персонифицированной кардиологии?

• Pavlova Tatyana V.
• Duplyakov Dmitriy V.

Abstract

Сoronary heart disease recrudescence is attended by severe hemostasis activation through plasma element. That requires usage of drugs for coagulation cascade blocking. For many years for this purpose in the acute period doctors used heparins (unfractionated heparin and low-molecular-weight heparins). Emergence of direct oral anticoagulants allows to protract anticoagulant treatment phase in patients with acute coronary syndrome (ACS). However, the only drug from this group that have demonstrated effectiveness in reducing overall mortality in these group of patients is rivaroxaban. The article describes main stages of the drug study and clinical researches results, allow registered indication for the use of rivaroxaban in patients after ACS.

Keywords:acute coronary syndrome, anticoagulants, rivaroxaban

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)